|
Feb 26
|
Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA
|
|
Feb 26
|
The Zacks Analyst Blog Highlights Charles Schwab, Gilead, Medtronic, Cooper-Standard and Rave Restaurant
|
|
Feb 26
|
Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors
|
|
Feb 25
|
Top Stock Reports for Charles Schwab, Gilead Sciences & Medtronic
|
|
Feb 25
|
Morgan Stanley sees FDA approval of GILD's Lenacapavir
|
|
Feb 25
|
4 PEG-Based GARP Picks to Weather 2025 Market Uncertainty
|
|
Feb 25
|
Gilead’s lenacapavir applications for HIV gain EMA validation
|
|
Feb 24
|
European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention
|
|
Feb 23
|
Gilead Sciences, Inc. (GILD): Among Renaissance Technologies Portfolio’s Top Stock Picks
|
|
Feb 21
|
Gilead’s lenacapavir under priority review could revolutionise HIV PrEP
|
|
Feb 21
|
Some Investors May Be Willing To Look Past Gilead Sciences' (NASDAQ:GILD) Soft Earnings
|
|
Feb 20
|
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
|
|
Feb 20
|
GILD or VRTX: Which Is the Better Value Stock Right Now?
|
|
Feb 20
|
Gilead Sciences, Inc. (GILD): Among Stocks That Analysts Think Will Go Up
|
|
Feb 20
|
Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?
|
|
Feb 20
|
High Growth Tech Stocks in the United States to Watch
|
|
Feb 19
|
Biotech Stock Roundup: MRNA's Q4 Results, GILD's Update & Other News
|
|
Feb 18
|
Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP use
|
|
Feb 18
|
Gilead Sciences Full Year 2024 Earnings: Beats Expectations
|
|
Feb 18
|
Deutsche Bank upgrades Gilead on its HIV treatment franchise
|